ESR1 and breast cancer: Given that the results indicate that CAND1 correlates with worse prognosis in ERα-positive breast cancer and that significantly higher CAND1 occurs in ERα-positive breast cancer patients who received hormone therapy compared to ERα-positive breast cancer patients who did not receive hormone therapy, clinicians should be aware when using hormone therapy to treat ERα-positive breast cancer patients, as it might increase CAND1 expression in patients.